Salem Investment Counselors Inc. lessened its position in shares of Cencora, Inc. (NYSE:COR – Free Report) by 3.8% in the fourth quarter, HoldingsChannel.com reports. The fund owned 1,092 shares of the company’s stock after selling 43 shares during the period. Salem Investment Counselors Inc.’s holdings in Cencora were worth $245,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in COR. Concord Wealth Partners bought a new stake in shares of Cencora during the 3rd quarter worth approximately $30,000. SYSTM Wealth Solutions LLC bought a new position in Cencora in the 2nd quarter valued at approximately $36,000. Ashton Thomas Securities LLC bought a new position in Cencora in the 3rd quarter valued at approximately $41,000. Fairscale Capital LLC bought a new position in Cencora in the 2nd quarter valued at approximately $54,000. Finally, Modus Advisors LLC bought a new position in Cencora in the 4th quarter valued at approximately $54,000. Institutional investors own 97.52% of the company’s stock.
Cencora Trading Up 1.8 %
COR opened at $240.36 on Wednesday. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $253.27. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The company has a fifty day moving average of $237.95 and a 200-day moving average of $233.65. The stock has a market cap of $46.46 billion, a PE ratio of 32.01, a price-to-earnings-growth ratio of 1.54 and a beta of 0.49.
Cencora Increases Dividend
Wall Street Analysts Forecast Growth
Several equities analysts recently commented on COR shares. UBS Group increased their price objective on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Wells Fargo & Company dropped their price objective on shares of Cencora from $249.00 to $237.00 and set an “equal weight” rating for the company in a research note on Friday, December 13th. StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Barclays upped their price target on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Finally, Mizuho initiated coverage on shares of Cencora in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price target for the company. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and a consensus target price of $275.60.
View Our Latest Analysis on COR
Insider Transactions at Cencora
In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the firm’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the sale, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Chairman Steven H. Collis sold 50,000 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the sale, the chairman now owns 326,557 shares of the company’s stock, valued at $79,670,111.29. The trade was a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 94,696 shares of company stock worth $22,862,734 over the last three months. 15.80% of the stock is owned by company insiders.
Cencora Profile
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
See Also
- Five stocks we like better than Cencora
- How to Calculate Inflation Rate
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- What is the MACD Indicator and How to Use it in Your Trading
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- What is the Euro STOXX 50 Index?
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.